


**BUY**

Current Price	440
Target Price	535
Upside/Downside	22%
52 Week Range	592/430

**Key Share Data**

Market Cap (Rs.bn)	45.72
Market Cap (US\$ mn)	666.23
No of o/s shares (mn)	106.0
Face Value	10
Monthly Avg.vol (BSE+NSE) Nos'000	26.72
BSE Code	540222
NSE Code	LAURUSLABS
Bloomberg	LAURUS:IN

**Price performance**

% Shareholding	Jun-18	Mar-18
Promoters	32.06	30.60
FII	10.85	7.80
DII	42.26	41.50
Others	14.83	20.10
<b>Total</b>	<b>100</b>	<b>100</b>

**Key Financials**

Year	Sales	% Growth	EBIDTA	OPM (%)	PAT	% Growth	EPS	PE (x)	RoE (%)	RoCE (%)
FY16	17775.8	34%	3622.0	20.4%	1337.4	95%	12.65	5.2	17%	15%
FY17	19046.5	7%	4076.4	21.4%	1902.8	42%	17.99	24.5	14%	15%
FY18	20690.0	9%	4133.2	20.0%	1676.1	-12%	15.81	27.8	11%	13%
FY19E	24576.8	19%	3788.1	15.4%	1395.5	-17%	13.16	33.4	9%	11%
FY20E	34526.0	40%	6852.1	19.8%	3461.1	148%	32.64	13.5	18%	20%

Laurus Labs Q1FY19 results were below estimates. While revenues were in line with estimates, the decline in earnings was more than our anticipation, in view of increase in raw materials imported from China and higher overheads from the FDF plant.

**Profitability drops amidst higher raw material costs and overheads**

Revenues increased 10% yoy (-4% qoq) to Rs 5390 mn. The API revenues increased 7% to Rs 4608 mn. While ARVs grew 37% yoy (+2% qoq) to Rs 3710 mn, Hep C declined further (-37% qoq) to Rs 241 mn. The Oncology APIs increased 19% qoq (flat yoy) to Rs 441 mn. Custom Synthesis increased 65% yoy (14% qoq) to Rs 541 mn. The ingredients business was 24% yoy around Rs 190 mn.

Gross Profit increased 5% to Rs 2439 mn. Gross margins declined to 45.2% in view of the 14% increase in raw material costs. EBITDA degrew 17% yoy (-31% qoq) in view of higher employee costs & R & D expenses.

With the commissioning of the formulations plant, depreciation was higher at 382 mn. Interest was higher at Rs 223 mn. PBT declined 59% yoy (-65% qoq) to Rs 229 mn. PAT was 65% lower at Rs 165 mn. EPS for the quarter was at Rs 1.65.

**Outlook & Valuation**

The recent commissioning of the formulations plant has increased overheads, which along with the increase in raw material prices have brought down profitability. Laurus Labs has been able to partially pass on the price increases, with a balance hit to the company. We believe this is a temporary phase which may last a quarter or two till the formulations and custom synthesis business scales up. The pace of the scale up is important to the progress of Laurus Labs, as 40% of its assets are currently not generating revenue. With the recent approvals to ARVs and Metformin, the management is confident of scale up from H2FY19.

At Rs 440, Laurus Labs trades at 14x FY20E EPS of Rs 32. We are cautious about the business developments at Laurus Labs. The uncertainties around business and execution have increased the risk in the investment. We reduce our estimates and target price to Rs 535. We recommend investors to BUY Laurus Labs with a long term target price of Rs 535.



Rs in mn	Q1FY19	Q4FY18	Q1FY18	yoy	qoq	FY18	FY17	Var %
<b>Income from operations</b>	<b>5390.0</b>	<b>5602.4</b>	<b>4912.2</b>	<b>10%</b>	<b>-4%</b>	<b>20690.0</b>	<b>19046.5</b>	<b>9%</b>
Material Cost	2951.5	2909.2	2585.2			10765.4	9967.7	
Employee Cost	728.1	672.3	627.2			2580.5	2462.3	
Research & Devt	345.0	442.0	229.0			1196.0	1402.0	
Other expenses	560.0	410.1	505.7			2,015.0	1,138.2	
<b>EBITDA</b>	<b>805.4</b>	<b>1168.8</b>	<b>965.1</b>	<b>-17%</b>	<b>-31%</b>	<b>4133.2</b>	<b>4076.4</b>	<b>1%</b>
<i>EBITDA margin</i>	<i>14.9%</i>	<i>20.9%</i>	<i>19.6%</i>			<i>20.0%</i>	<i>21.4%</i>	
Depreciation	381.9	346.1	297.9			1254.5	1059.8	
Interest	223.2	232.6	191.0			796.4	999.0	
Other Income	25.9	50.8	75.4			291.9	334.4	
<b>Profit before tax</b>	<b>226.1</b>	<b>640.9</b>	<b>551.7</b>	<b>-59%</b>	<b>-65%</b>	<b>2374.2</b>	<b>2352.0</b>	<b>1%</b>
Tax	60.7	190.1	162.7			698.1	438.6	
Share of Profit/(Loss)	0.0	0.0	0.0			0.0	-10.6	
<b>Profit after tax</b>	<b>165.4</b>	<b>450.8</b>	<b>389.1</b>	<b>-57%</b>	<b>-63%</b>	<b>1676.1</b>	<b>1902.8</b>	<b>-12%</b>
Equity	1060.3	1060.3	1057.6			1060.3	1057.6	
Number of shares	106.0	106.0	105.8			106.0	105.8	
EPS - Diluted(Rs)	1.6	4.3	3.7			15.8	18.0	

### Key takeaways from the concall

1. Profitability declined due to increase in raw material cost from China, lower sales of contract manufacturing APIs, unfavourable product mix and higher exchange rate for imports.
2. Laurus Labs is working towards backward integration with alternative supplies and in-house manufacturing, in order to reduce its dependence on imports from China. The company expects partial improvement in Q2 and restoration of EBITDA margins from Q3FY19.
3. The company has received tentative approval from The Global Fund, for Efavirenz.
4. Laurus Labs filed 13 ANDAs during the quarter.
5. The company expects to start Metformin supplies to US from Q2FY19.
6. Laurus Labs expects to receive 2 approvals from USFDA.



**DALAL & BROACHA**  
STOCK BROKING PVT. LTD.

Result update@ Dalal & Broacha

**LAURUS LABS FINANCIALS**

<b>PROFIT &amp; LOSS (Rs mn)</b>	<b>FY16</b>	<b>FY17</b>	<b>FY18</b>	<b>FY19E</b>	<b>FY20E</b>	<b>CASH FLOW</b>	<b>FY16</b>	<b>FY17</b>	<b>FY18</b>	<b>FY19E</b>	<b>FY20E</b>
<b>Revenue from Operations (Net)</b>	17775.8	19046.5	20690.0	24576.8	34526.0	<b>Profit After Tax</b>	1337.4	1902.8	1676.1	1395.5	3461.1
Raw Material Costs	10081.6	9967.7	10765.4	13517.2	18644.1	Add: Depreciation	864.1	1059.8	1254.5	1212.6	1381.3
<b>Gross Profit</b>	<b>7694.2</b>	<b>9078.8</b>	<b>9924.7</b>	<b>11059.6</b>	<b>15882.0</b>	<b>Cash Profits</b>	<b>2201.4</b>	<b>2962.6</b>	<b>2930.6</b>	<b>2608.0</b>	<b>4842.4</b>
Gross Margins	43.3%	47.7%	48.0%	45.0%	46.0%	(Increase)/ Decrease in:-					
Employee Benefits Expenses	1,885.2	2,462.3	2,580.5	3,096.6	3,715.9	Trade receivables	-1,597.9	-1,227.5	-29.8	-354.2	-2,453.2
Other Manufacturing Expenses	757.4	781.1	805.5	886.1	974.7	Long Term Loans & Advances	1,185.6	0.0	-8.3	-1.7	-2.0
Research & Development Expenses	796.2	1,402.0	1,196.0	1,474.6	2,071.6	Short Term Loans & Advances	-268.0	-80.0	-184.0	-127.4	-326.1
Operating and Selling Expenses	633.5	357.1	1,209.5	1,814.2	2,267.7	Other current assets	-268.0	-80.0	-184.0	-127.4	-326.1
<b>EBITDA</b>	<b>3622.0</b>	<b>4076.4</b>	<b>4133.2</b>	<b>3788.1</b>	<b>6852.1</b>	Inventories	-116.0	-219.5	-757.4	-1,003.4	-2,087.7
Depreciation and Amortisation	864.1	1059.8	1254.5	1212.6	1381.3	Trade payables	168.0	154.9	492.3	394.9	1,079.0
<b>EBIT</b>	<b>2757.9</b>	<b>3016.5</b>	<b>2878.7</b>	<b>2575.6</b>	<b>5470.8</b>	Short term provisions	-15.5	-29.5	-2.3	8.4	21.5
Finance Expenses	1,111.1	999.0	796.4	900.2	900.2	Other current liabilities	-1,161.9	413.1	253.0	157.4	402.8
Other Income	43.6	334.4	291.9	262.7	236.5	Other Non Current Assets	-450.4	87.4	62.8	-44.0	-48.4
<b>Profit Before Tax</b>	<b>1690.4</b>	<b>2352.0</b>	<b>2374.2</b>	<b>1938.1</b>	<b>4807.1</b>	Other Long Term Liabilities	-281.9	466.1	16.3	64.7	71.2
Tax Expense	349.0	438.6	698.1	542.7	1346.0	Long Term Provision	16.5	78.2	62.5	39.1	100.2
Share of results of associate	-4.02	-10.55	0	0	0	<b>Working Capital change</b>	<b>-2,789.6</b>	<b>-436.9</b>	<b>-278.9</b>	<b>-993.5</b>	<b>-3,569.0</b>
<b>Profit for the year</b>	<b>1337.4</b>	<b>1902.8</b>	<b>1676.1</b>	<b>1395.5</b>	<b>3461.1</b>	Net Cash generated from operations	<b>1,711.3</b>	<b>2,094.8</b>	<b>2,540.1</b>	<b>324.7</b>	<b>2,690.6</b>
						Net Cash from Investing activities	-3117.3	-3767.0	-3896.8	353.3	-2553.3
						Net Cash (used in)/ generated from financing activities	<b>1,104.9</b>	<b>1,425.4</b>	<b>1,346.4</b>	<b>-245.4</b>	<b>-301.0</b>
<b>BALANCE SHEET</b>						Net increase/(decrease) in cash and cash equivalents	<b>-301.1</b>	<b>-246.8</b>	<b>-10.3</b>	<b>432.5</b>	<b>-163.6</b>
Share Capital	157.7	1057.6	1060.3	1060.3	1060.3	Cash & Cash equivalents at the beginning of the year	588.9	287.7	40.9	30.6	463.1
Reserves & Surplus	7,744.2	12,246.9	13,766.1	14,851.4	17,940.4	Cash & Cash equivalents at the end of the year	287.7	40.9	30.6	463.1	299.5
<b>Net Worth</b>	<b>7901.9</b>	<b>13304.5</b>	<b>14826.4</b>	<b>15911.7</b>	<b>19000.7</b>						
Preference Shares	666.1	0.0	0.0	0.0	0.0	<b>Ratios</b>					
Long term Borrowings	4,597.4	1,245.6	1,416.6	1,416.6	1,416.6	OPM	20.4%	21.4%	20.0%	15.4%	19.8%
Short term Borrowings	4,814.2	6,441.7	7,585.2	7,585.2	7,585.2	NPM	7.5%	10.0%	8.1%	5.7%	10.0%
<b>TOTAL DEBT</b>	<b>9,411.6</b>	<b>7,687.3</b>	<b>9,001.8</b>	<b>9,001.8</b>	<b>9,001.8</b>	Tax rate	21%	19%	29%	28%	28%
Other Long-term liabilities	164.7	630.7	647.0	711.7	782.8						
Deferred tax Liabilities (Net)	0.0	0.0	0.0	0.0	0.0	<b>Growth Ratios (%)</b>					
<b>CAPITAL EMPLOYED</b>	<b>18144.2</b>	<b>21622.5</b>	<b>24475.1</b>	<b>25625.1</b>	<b>28785.3</b>	Net Sales	34%	7%	9%	19%	40%
						Operating Profit	81%	13%	1%	-8%	81%
						PAT	95%	42%	-12%	-17%	148%
Tangible assets - Gross	10,980.4	13,963.8	15,463.8	17,963.8	20,463.8	<b>Per Share (Rs.)</b>					
Acc. Depreciation	834.0	1,840.4	3,094.9	4,307.5	5,688.8	Net Earnings (EPS) - Diluted	12.6	18.0	15.8	13.2	32.6
<b>Net Block - Tangibles</b>	<b>10,146.4</b>	<b>12,123.4</b>	<b>12,368.9</b>	<b>13,656.3</b>	<b>14,775.0</b>	Cash Earnings (CPS) - Diluted	20.8	28.0	27.7	24.7	45.8
<b>Net Block - Intangibles</b>	<b>63.9</b>	<b>78.5</b>	<b>71.6</b>	<b>75.2</b>	<b>78.9</b>	Number of shares	15.8	105.8	106.0	106.0	106.0
Capital Work in Progress	696.0	1432.6	1631.8	1000.0	1000.0	Book Value	501.2	125.8	139.8	150.1	179.2
<b>Total Fixed Assets</b>	<b>10,906.3</b>	<b>13,634.5</b>	<b>14,072.3</b>	<b>14,731.5</b>	<b>15,853.9</b>	Free Cash Flow	31.8	18.9	9.8	-20.5	1.8
Goodwill	0.00	97.39	97.39	97.39	97.39	<b>Valuation Ratios</b>					
Non-current Investment	70.5	34.1	34.1	34.1	34.1	P/E(x)	5.2	24.5	27.8	33.4	13.5
Other non-current assets	1146.3	1214.4	978.9	1023.9	1073.4	P/B(x)	5.8	3.5	3.1	2.9	2.4
Current Investments	0.0	0.0	0.0	1500.0	500.0	EV/EBIDTA(x)	15.4	13.3	13.4	14.5	8.1
<b>Current assets</b>						EV/SALES (x)	3.1	2.8	2.7	2.2	1.6
Inventories	4,870.9	5,090.5	5,847.8	6,851.2	8,938.9	<b>FCF Yield(%)</b>	1%	4%	2%	-5%	0%
Trade receivables	4,448.6	5,676.1	5,705.9	6,060.0	8,513.3	<b>Return Ratios (%)</b>					
<b>Cash and bank balance</b>	<b>287.7</b>	<b>40.9</b>	<b>30.6</b>	<b>463.1</b>	<b>299.5</b>	ROE	17%	14%	11%	9%	18%
<b>Total Loans &amp; Advances</b>	<b>90.7</b>	<b>0.0</b>	<b>8.3</b>	<b>9.9</b>	<b>11.9</b>	ROCE	15%	15%	13%	11%	20%
Other current assets	414.3	494.3	678.2	805.7	1,131.8						
<b>Total Current assets</b>	<b>9,824.5</b>	<b>11,260.8</b>	<b>12,240.2</b>	<b>13,726.8</b>	<b>18,595.9</b>						
<b>Current liabilities</b>											
Trade payables	2476.1	2631.0	3123.3	3518.2	4597.2						
Other current liabilities	1470.7	2087.7	2315.7	2620.8	3186.2						
Short term provisions	76.5	47.1	44.7	53.1	74.7						
Long term provisions	67.7	145.9	208.4	247.5	347.7						
<b>Total Current Liabilities</b>	<b>4091.0</b>	<b>4911.7</b>	<b>5692.1</b>	<b>6439.7</b>	<b>8205.8</b>						
Working Capital	5733.5	6349.1	6548.1	7287.1	10390.1						
<b>CAPITAL DEPLOYED</b>	<b>18,144.2</b>	<b>21,370.3</b>	<b>21,761.3</b>	<b>25,137.1</b>	<b>28,248.4</b>						



**DALAL & BROACHA**  
STOCK BROKING PVT. LTD.

**Result update@ Dalal & Broacha**

#### Disclaimer

**Dalal & Broacha Stock Broking Pvt Ltd, hereinafter referred to as D& B** (CIN\_U67120MH1997PTC111186) was established in 1997 and is an integrated financial services player offering an extensive range of financial solutions and services to a wide spectrum of customers with varied needs ranging from equities to mutual funds to depository services.

D&B is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE). D&B along with its affiliates offers the most comprehensive avenues for investments and is engaged in the securities businesses including stock broking (Institutional and retail), depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. [www.dalal-broacha.com](http://www.dalal-broacha.com)

D&B is registered as Research Analyst with SEBI bearing registration Number INH000001246 as per SEBI (Research Analysts) Regulations, 2014.

D&B hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in any time in the past. It has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

SEBI and Stock Exchanges have conducted the routine inspection and based on their observations have issued advice letters or levied minor penalty on D&B for certain operational deviations in routine course of business.

D&B offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

#### **Other disclosures by D&B (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report:-**

D&B or its associates may have financial interest in the subject company.

D&B or its associates do not have any material conflict of interest in the subject company.

The Research Analyst or Research Entity (D&B) has not been engaged in market making activity for the subject company.

D&B or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report.

#### **Disclosures in respect of Research Analyst:**

Whether Research Analyst or his/her relatives have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report:	No
Whether the Research Analyst or his/her relative's financial interest in the subject company.	No
Whether the research Analyst has served as officer, director or employee of the subject company	No
Whether the Research Analyst has received any compensation from the subject company in the past twelve months	No
Whether the Research Analyst has managed or co-managed public offering of securities for the subject company in the past twelve months	No
Whether the Research Analyst has received any compensation for investment banking or	No



**DALAL & BROACHA**  
STOCK BROKING PVT. LTD.

**Result update@ Dalal & Broacha**

merchant banking or brokerage services from the subject company in the past twelve months	
Whether the Research Analyst has received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months	No
Whether the Research Analyst has received any compensation or other benefits from the subject company or third party in connection with the research report	No

D&B and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that may be inconsistent with the recommendations expressed herein.

In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject D&B or its group companies to any registration or licensing requirement within such jurisdiction. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom. All material presented in this report, unless specifically indicated otherwise, is under copyright to D&B. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of D&B. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of D&B or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

Contact	Email ID	Contact No.	Sector
Mr. Kunal Bhatia	<a href="mailto:kunal.bhatia@dalal-broacha.com">kunal.bhatia@dalal-broacha.com</a>	022 67141442	Auto, Auto Ancillary, FMCG
Ms.Charulata Gaidhani	<a href="mailto:charulata.gaidhani@dalal-broacha.com">charulata.gaidhani@dalal-broacha.com</a>	022 67141446	Pharma /Healthcare
Ms. Abhilasha Satale	<a href="mailto:Abhilasha.satale@dalal-broacha.com">Abhilasha.satale@dalal-broacha.com</a>	02267141439	Mid Cap Analyst
Mr. Mayank Babla	<a href="mailto:mayank.babla@dalal-broacha.com">mayank.babla@dalal-broacha.com</a>	022 67141412	IT, Media & Telecom
Mr. Avinash Kumar	<a href="mailto:avinash.kumar@dalal-broacha.com">avinash.kumar@dalal-broacha.com</a>	022 67141441	Capital Goods
Ms. Richa.Singh	<a href="mailto:richa.singh@dalal-broacha.com">richa.singh@dalal-broacha.com</a>	022 67141444	Analyst

Address: - 508, Maker Chambers V, 221 Nariman Point, Mumbai 400 021  
Tel: 91-22- 2282 2992, 2287 6173, (D) 6630 8667 Fax: 91-22-2287 0092

E-mail: [research@dalalbroachaindia.com](mailto:research@dalalbroachaindia.com), [equity.research@dalal-broacha.com](mailto:equity.research@dalal-broacha.com)